CHEMOPREVENTION FOR PROSTATE CANCER IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA WITH ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS
https://doi.org/10.17650/1726-9776-2013-9-4-22-24
Abstract
The paper gives the comparative results of chemoprevention against prostate cancer (PC) in 189 patients with benign prostate hyperplasia with a prostate-specific antigen (PSA) level of 2.5 to 10.0 ng/ml during 4‑year combined (avodart + omnic) or monotherapy with either drug. Biopsy revealed PC in 14.3 % of the patients treated with avodart and in 29.0 % of those who received omnic monotherapy (p < 0.05). In the avodart groups, the incidence rate of aggressive PC was almost twice the rate in the omnic monotherapy group. The long-term avodart therapy was safe with a stable reduction in the baseline levels of PCA and dihydrotestosterone, and conversely, any PSA rise and even an episodic fall in free PSA ratio are indications for transrectal multifocal prostate biopsy.
About the Authors
Yu. I. Kushniruk
Research and Practical Center for Preventive and Clinical Medicine, State Administration of Affairs, Kiev
Ukraine
Ukraine
V. A. Yarosh
Research and Practical Center for Preventive and Clinical Medicine, State Administration of Affairs, Kiev
Ukraine
Ukraine
M. D. Dyachuk
Research and Practical Center for Preventive and Clinical Medicine, State Administration of Affairs, Kiev
Ukraine
Ukraine
References
1. Jemal A., Siegel R., Ward E. et al. Cancer statistic 2006. CA Cancer J Clin 2006;56(2): 106–30.
2. Говоров А. В., Пушкарь Д. Ю., Курджиев М. А. и др. Результаты повторной биопсии предстательной железы у больных раком предстательной железы низкого риска. Онкоурология. Материалы III конгресса РООУ. Москва, 2008; с. 37.
3. Аполихин О. И., Сивков А. В., Башлиев Д. А. и др. Анализ урологической заболеваемости в Российской Федерации в 2002–2009 годах по данным официальной статистики. Экспер и клин урол 2011:(1): 4–10.
4. Klotz L. H. Active surveillance with selective delayed intervention. Can J Urol 2005;12 (Suppl. 1):53–7.
5. Walsh P. C. Chemoprevention of prostate cancer. N Engl J Med 2010;362: 1237–8.
6. Rittmaster R. S., Fleshner N. E., Thompson J. M. Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol 2009;55:1064–74.
7. Сивков А. В., Жернов А. А., Кешишев Н. Г., Шкабко О. В. Место ингибиторов 5α-редуктазы в химиопрофилактике рака предстательной железы. Экспер и клин урол 2012;(2):52–7.
8. Shröder F. H., Roobol M. J. The REDUCE Trial. Eur Urol 2010;58:253–5.
9. Кушнирук Ю. И., Ярош В. А., Сорока В. В. Влияние аводарта и омника на динамику простатспецифичного антигена и результаты положительных биопсий при 4‑летнем лечении ими пациентов с доброкачественной гиперплазией предстательной железы с высоким риском развития рака. Онкоурология. Материалы VI конгресса РООУ. Москва, 2011; с. 101–102.
10. Kushniruk Y. I. The effects of the combination and monotherapy with dutasteride and tamsulosin on clinical outcomes and the diagnosis of prostate cancer in men with symptomatic benign prostatic hyperplasia: the results of 4‑year treatment. Клин онкол 2012;1:72.
11. Fleshner N., Zlotta A. Prostate cancer prevention. Past, present and future. Cancer 2007;110:1889–99.
12. Lippman S. M., Klein E. A., Goodman P. J. et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers. The selenium and vitamin E prevention Trial (SELECT). J Am Med Assoc 2009;301:39–51.
13. Syed D. N., Khan N., Afaq F., Mukhtar H. Chemoprevention of prostate cancer through dietary agents progress and promise. Canc Epidemiol Biomarkers Prev 2007;16:2193–203.
14. Tyndall D. J., Rittmaster R. S. The rationale for inhibiting 5 ‑α-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008; 179: 1235–42.
15. Thorpe J. E., Jain S., Marczylo T. H. et al. A review of phase III clinical trials of prostate cancer chemoprevention II. Ann R Coll Surg Engl 2007;89(3):207–11.
16. Andriole G., Bostwick D., Brawley O. et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172: 1314–7.
17. The Motion: All men over the age of 50 should be encouraged to take a 5‑α-reductase inhibitor to prevent prostate cancer. II For the motion L. Klotz. Eur Urol 2008;53:1079–83. Against the motion: Noel Clarke, Eur Urol 2008; 53: 1081–2.
Review
For citations:
Kushniruk Yu.I., Yarosh V.A., Dyachuk M.D. CHEMOPREVENTION FOR PROSTATE CANCER IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA WITH ELEVATED PROSTATE-SPECIFIC ANTIGEN LEVELS. Cancer Urology. 2013;9(4):22-24. (In Russ.) https://doi.org/10.17650/1726-9776-2013-9-4-22-24
Views:
2227
Email this article 